Posted by Michael Wonder on 30 Oct 2022
Another example of a “Shkrelian” drug price increase
28 October 2022 - The story of Martin Shkreli and the drug, Daraprim, has been used as an example of drug company greed. Daraprim is used to treat a parasitic disease known as toxoplasmosis, which can be life-threatening in people with compromised immune systems.
In 2015, Turing Pharmaceuticals, where Shkreli was CEO, acquired the rights to Daraprim from CorePharma, and promptly raised the price from $12.50 a tablet to $750.
